Multistage nanoparticle drug delivery system for the treatment of solid tumors

Patent metadata

Field	Value
Publication number	US-9919059-B2
Application number	US-201314102118-A
Country	US
Kind code	B2
Filing date	Dec 10, 2013
Priority date	Dec 10, 2012
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor.

First claim

We claim:

1. A polymer-drug conjugate defined by Formula I or Formula IV

or

wherein
A is, independently for each occurrence, a therapeutic, prophylactic or diagnostic agent;
S is absent, or is a spacer group;
X is a hydrophilic polymer segment comprising a graft copolymer, wherein the graft copolymer comprises a polymeric backbone comprising a poly(amino acid), wherein the backbone is functionalized by one or more hydrophilic polymeric side chains;
L is absent, or is a hydrolysable or enzymatically cleavable linking group;
Y is a hydrophobic polymer segment;
b and c are independently integers between 1 and 100,
A′ is, independently for each occurrence, anti-neoplastic drug;
X′ is a hydrophilic polymer segment comprising a graft copolymer, wherein the graft copolymer comprises a polymeric backbone comprising a poly(amino acid), wherein the backbone is functionalized by one or more hydrophilic polymeric side chains, wherein the graft copolymer has a grafting ratio of between about 1.5% and 60%;
Y′ is a poly(alkylene oxide) or copolymer thereof; and
wherein the conjugates are capable of forming nanoparticles having a diameter between about 80 nm and about 500 nm, having hydrophilic polymer on the outer surface and a hydrophobic polymer core, and wherein the nanoparticles release smaller nanoparticles upon exposure to hydrolysis or an enzyme in a tumor microenvironment.

2. The conjugate of claim 1 , wherein A is a small-molecule anti-neoplastic agent.

3. The conjugate of claim 2 , wherein A is an anthracycline or a topoisomerase inhibitor.

4. The conjugate of claim 1 , wherein Y comprises an aliphatic polyester.

5. The conjugate of claim 1 , wherein Y is selected from the group consisting of poly(lactide), poly(glycolide), poly(caprolactone), and copolymers thereof.

6. The conjugate of claim 1 , wherein the graft copolymer is functionalized by one or more poly(alkylene glycol) side chains.

7. The conjugate of claim 6 , wherein the poly(alkylene glycol) side chains comprise polyethylene glycol) or copolymers thereof.

8. The conjugate of claim 1 , wherein the poly(amino acid) is selected from the group consisting of polyglutamic acid, polyaspartic acid, polyserine, polylysine, copolymers thereof, and combinations thereof.

9. The conjugate of claim 1 , wherein the hydrolysable functional group is selected from the group consisting of an ester, an amide, and a glycosidic bond.

10. The conjugate of claim 1 , wherein the enzymatically cleavable group is an oligo- or poly(peptide) cleavable by matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), Cathepsin B, autotaxins, and combinations thereof.

11. A polymer drug conjugate defined by Formula II

wherein
A is a drug;
S is absent, or is a spacer group;
L is absent, or is a linking group;
D is, independently for each occurrence, O, S, or NR 1 ;
R 1 is H or a C 1 -C 12 alkyl group optionally containing between one and six oxygen heteroatoms;
a, b, and c are each, independently, an integer between 1 and 1000;
x and y are each, independently, an integer between 1 and 1000;
z is, independently for each occurrence, an integer between 1 and 1000; and
j and k are each, independently, an integer between 1 and 1000.

12. A polymer drug conjugate defined by Formula III

wherein
A is a drug;
S is absent, or is a spacer group;
L is absent, or is a linking group;
D is, independently for each occurrence, O, S, or NR 1 ;
R 1 is H or a C 1 -C 12 alkyl group optionally containing between one and six oxygen heteroatoms;
a, b, c, and d are each, independently, an integer between 1 and 1000;
x and y are each, independently, an integer between 1 and 1000;
z is, independently for each occurrence, an integer between 1 and 1000; and
j and k are each, independently, an integer between 1 and 1000.

13. A polymer drug conjugate defined by Formula V

wherein
A is a drug;
S is absent, or is a spacer group;
L is absent, or is a linking group;
D is, independently for each occurrence, O, S, or NR 1 ;
R 1 is H or a C 1 -C 12 alkyl group optionally containing between one and six oxygen heteroatoms;
a, b, c, and d are each, independently, an integer between 1 and 1000;
z is, independently for each occurrence, an integer between 1 and 1000; and
k is an integer between 1 and 1000.

14. The polymer-drug conjugate of claim 1 , formed into a nanoparticle or in a nanoparticle.

15. The polymer-drug conjugate claim 14 , wherein the nanoparticle has an average particle size of between 80 nm and 500 nm.

16. The nanoparticles defined by claim 15 , wherein the nanoparticles have an average particle size of between 100 nm and 200 nm.

17. A method of treating a solid tumor comprising administering to a subject in need thereof a formulation comprising the nanoparticles of claim 14 .

18. The method of claim 17 , wherein the formulation is administered by intravenous injection.

19. The method of claim 17 , wherein the formulation is administered by injection into the tumor, injection around the tumor, or combinations thereof.

20. The method of claim 17 , wherein the solid tumor is selected from the group consisting of adenocarcinomas, carcinomas, hemangiomas, liposarcomas, lymphomas, melanomas, and sarcomas.

21. The method of claim 17 , wherein the formulation is administered in an effective amount to slow tumor growth, halt tumor growth, or decrease tumor size.

22. The method of claim 17 , wherein the tumor vasculature is more permeable and/or of a larger diameter than the vasculature in normal tissue, and the nanoparticles have a mean average diameter larger than the average diameter of the vasculature of the normal tissue and smaller than the diameter of the tumor vasculature.

23. The conjugate of claim 1 , wherein the one or more polymeric side chains have the same or different polymeric compositions.

24. The conjugate of claim 1 , wherein the agent is released when the linker L is cleaved.

25. The conjugate of claim 24 wherein A is an anti-neoplastic agent.

26. The conjugate of claim 1 , wherein is selected from the group consisting of poly(ethylene glycol) and copolymers thereof.

Assignees

• Massachusetts Inst Technology
• The Massachusetts General Hospital
• Massachusetts Gen Hospital

Inventors

• Wong Cliff R
• Bawendi Moungi G
• Fukumura Dai
• Jain Rakesh K

Classifications

• A61K47/50

  the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates · CPC title

• A61K47/65

  Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title

• A61K47/55

  the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug · CPC title

• A61K47/6937 Primary

  the polymer being PLGA, PLA or polyglycolic acid · CPC title

• A61K47/6931

  the material constituting the nanoparticle being a polymer · CPC title